Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials
8 pending office actions • 8 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 6 patents granted in the last 365 days
UNIVERSITÄT BERN has 8 pending office actions in Biotechnology & Pharmaceuticals. The docket spans 8 distinct examiners and 8 distinct art units, showing complete numerical separation across the listed matters. No examiner or art unit appears to carry multiple matters in the supplied figures, so the portfolio is dispersed rather than concentrated.
BRIDGES, DONAVAN LEE is the busiest examiner, with 1 pending matter. That assignment is representative of the stated distribution, not a dominant share of the docket. Counsel should maintain a coordinated filing and response calendar while preparing each matter independently, because the examination record is likely to reflect different examiner practices and technical classifications.
The absence of shared assignments limits the value of a single examiner-focused prosecution strategy. Portfolio management is still useful for spotting timing conflicts, preserving consistent terminology, and aligning claim-scope decisions across related technologies. However, the data does not establish that the applications share claim language, prior art, or substantive objections, so those issues should be tested from the individual office actions.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (38%) |
| §112 only | 1 (12%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BRIDGES, DONAVAN LEE | 1 | — | — |
| KIM, YOUNG J | 1 | 64.8% | +18.2% |
| DIETZ, NOE ROBERT | 1 | 0.0% | +0.0% |
| WARD, AARON DUREL | 1 | 0.0% | +0.0% |
| LEE, JIA-HAI | 1 | 49.0% | +46.9% |
| ILLING, CAITLIN NORINE | 1 | 47.9% | +38.9% |
| BREEN, KIMBERLY CATHERINE | 1 | 23.8% | +56.3% |
| JOHANNSEN, DIANA B | 1 | 53.2% | +42.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 7 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18705292 | MICROFLUIDIC CELL CULTURING DEVICE | BRIDGES, DONAVAN LEE | — |
| 18704678 | JUP BIOMARKER FOR THE DIAGNOSIS OF DISEASES OR DISORDERS OF THE FEMALE REPRODUCTIVE TRACT | KIM, YOUNG J | — |
| 18700883 | SLEEP-BASED DETECTION AND INTERVENTION SYSTEM | DIETZ, NOE ROBERT | — |
| 18691491 | MINOR SPLICEOSOME TARGETING COMPOSITIONS AND THEIR USE IN CANCER TREATMENT | WARD, AARON DUREL | — |
| 18565545 | 3D PRINTING OF SOLID-STATE PHANTOMS | ILLING, CAITLIN NORINE | — |
| 18561525 | REDOX SENSITIVE CRALBP MUTANT PROTEINS | BREEN, KIMBERLY CATHERINE | — |
| 18016601 | PROGNOSTIC BIOMARKERS FOR CANCER | JOHANNSEN, DIANA B | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18704678 | JUP BIOMARKER FOR THE DIAGNOSIS OF DISEASES OR DISORDERS OF THE FEMALE REPRODUCTIVE TRACT | KIM, YOUNG J | — |
| 18545392 | NANOSPHERES OF SEC14-LIKE PROTEINS AND COGNATE LIGANDS | LEE, JIA-HAI | — |
| 18565545 | 3D PRINTING OF SOLID-STATE PHANTOMS | ILLING, CAITLIN NORINE | — |
| 18561525 | REDOX SENSITIVE CRALBP MUTANT PROTEINS | BREEN, KIMBERLY CATHERINE | — |
| 18016601 | PROGNOSTIC BIOMARKERS FOR CANCER | JOHANNSEN, DIANA B | — |
| Art Unit | Apps |
|---|---|
| 1758 | 1 |
| 1681 | 1 |
| 3791 | 1 |
| 1636 | 1 |
| 1658 | 1 |
| 1767 | 1 |
| 1657 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18705292 | MICROFLUIDIC CELL CULTURING DEVICE | BRIDGES, DONAVAN LEE | 1758 | §102§103§112 | Non-Final OA | — | Pending | Apr 26, 2024 |
| 18704678 | JUP BIOMARKER FOR THE DIAGNOSIS OF DISEASES OR DISORDERS OF THE FEMALE REPRODUCTIVE TRACT | KIM, YOUNG J | 1681 | §101§102§103§112 | Non-Final OA | — | Pending | Apr 25, 2024 |
| 18700883 | SLEEP-BASED DETECTION AND INTERVENTION SYSTEM | DIETZ, NOE ROBERT | 3791 | §102§103§112 | Non-Final OA | — | Pending | Apr 12, 2024 |
| 18691491 | MINOR SPLICEOSOME TARGETING COMPOSITIONS AND THEIR USE IN CANCER TREATMENT | WARD, AARON DUREL | 1636 | §101§102§103§112 | Non-Final OA | — | Pending | Mar 13, 2024 |
| 18545392 | NANOSPHERES OF SEC14-LIKE PROTEINS AND COGNATE LIGANDS | LEE, JIA-HAI | 1658 | §102§103§112DP | Final Rejection | — | Pending | Dec 19, 2023 |
| 18565545 | 3D PRINTING OF SOLID-STATE PHANTOMS | ILLING, CAITLIN NORINE | 1767 | §103§112 | Non-Final OA | — | Pending | Nov 30, 2023 |
| 18561525 | REDOX SENSITIVE CRALBP MUTANT PROTEINS | BREEN, KIMBERLY CATHERINE | 1657 | §112 | Final Rejection | — | Pending | Nov 16, 2023 |
| 18016601 | PROGNOSTIC BIOMARKERS FOR CANCER | JOHANNSEN, DIANA B | 1682 | §101§103§112 | Final Rejection | — | Pending | Jan 17, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialUNIVERSITÄT BERN has 8 pending office actions as of October 2026, spread across 8 art units and 8 examiners.
Donavan Lee Bridges has the most, with 1 of UNIVERSITÄT BERN's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
